Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „treated“
Suchtreffer
Begriffe & Kennungen
Adcirca (previously Tadalafil Lilly) · 4.8 · 27 weight cohort, ≥ 25 kg to < 40 kg) or 40 mg (heavy-weight cohort, ≥ 40 kg), and 18 patients were treated wi
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · A total of 51 paediatric patients aged from 2.5 to 17 years with PAH were treated with tadalafil in clinical t
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · A total of 51 paediatric patients aged from 2.5 to 17 years with PAH were treated with tadalafil in clinical t
Eintrag öffnenAdtralza · 4.8 · Eczema herpeticum Eczema herpeticum was reported in 0.3% of the subjects treated with tralokinumab and in 1.5%
Eintrag öffnenAdtralza · 4.8 · Eosinophilia Adverse reactions of eosinophilia were reported in 1.3% of patients treated with tralokinumab and
Eintrag öffnenAdtralza · 4.8 · Keratitis was reported in 0.5% of subjects treated with tralokinumab during the initial treatment period. Of t
Eintrag öffnenAdvate · 4.8 · Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with fact
Eintrag öffnenAdvate · 4.8 · Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with fact
Eintrag öffnenAdvate · 4.8 · Of the 229 treated patients who were assessed for antibodies to Chinese hamster ovary (CHO) cell protein, 3 sh
Eintrag öffnenAdvate · 4.8 · Of the 229 treated patients who were assessed for antibodies to Chinese hamster ovary (CHO) cell protein, 3 sh
Eintrag öffnenAdynovi · 4.8 · 6 previously-untreated patients (PUPs), who received at least one dose of ADYNOVI in 7 completed multi-centre,
Eintrag öffnenAdynovi · 4.8 · Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with fact
Eintrag öffnenAdynovi · 4.8 · Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with fact
Eintrag öffnenAfinitor · 4.8 · In the safety pooling, 37% of the Afinitor-treated patients were ≥65 years of age. The number of patients with
Eintrag öffnenAfinitor · 4.8 · The safety profile is based on pooled data from 2,879 patients treated with Afinitor in eleven clinical studie
Eintrag öffnenAfqlir · 4.8 · The most frequently observed adverse reactions (in at least 5% of patients treated with aflibercept) were conj
Eintrag öffnenAfqlir · 4.8 · The most frequently observed adverse reactions (in at least 5% of patients treated with aflibercept) were conj
Eintrag öffnenAfstyla · 4.8 · Development of neutralizing antibodies (inhibitors) may occur in patients with haemophilia A treated with fact
Eintrag öffnenAhzantive · 4.8 · The most frequently observed adverse reactions (in at least 5% of patients treated with aflibercept) were conj
Eintrag öffnenAhzantive · 4.8 · The most frequently observed adverse reactions (in at least 5% of patients treated with aflibercept) were conj
Eintrag öffnen